肝细胞癌
顺铂
纳米医学
医学
免疫原性细胞死亡
癌症研究
免疫系统
药理学
药品
蛋白激酶A
抗药性
激酶
化疗
免疫疗法
化学
内质网
阿霉素
程序性细胞死亡
细胞凋亡
硝普钠
下调和上调
酪氨酸激酶
遗传增强
一氧化氮
细胞毒性
药物输送
作者
Xuqi Peng,Yating Zheng,Xiran Gui,Xiaomin Liu,Zhenwen Zhao,Yihang Yuan,Ye Peng,Haitao Cai,Jinyang Wang,Jianlin Ge,Hui Liu,Haitian Tang,Fan Dai,Aijun Jiang,Ruirui Fan,Yesi Shi,Chengchao Chu,Pan He,Yang Zhang,Gang Liu
出处
期刊:
[Elsevier BV]
日期:2026-01-20
卷期号:2 (9): 100338-100338
被引量:4
标识
DOI:10.1016/j.celbio.2025.100338
摘要
Hepatocellular carcinoma (HCC) is notoriously resistant to conventional chemotherapy and immunotherapy. This study presents a strategy that reprograms cisplatin into a chemoimmunotherapeutic agent by combining it with ZnNO, a fully active nanomedicine composed of sodium nitroprusside and zinc ions. Mechanistically, ZnNO enhances cisplatin chemosensitivity by depleting glutathione and releasing nitric oxide, while Zn²⁺ restores cisplatin-induced immunogenic cell death by activating endoplasmic reticulum stress via the PERK-eukaryotic translation initiation factor 2α (eIF2α) pathway. This dual modulation reactivates antigen presentation and promotes in situ antitumor immunity. Co-encapsulation of ZnNO and cisplatin in a thermosensitive nanoemulsion hydrogel enables transarterial chemoimmunoembolization, achieving sustained drug release, vascular embolization, and immune activation that downregulates drug resistance markers (MRP2 and Slc22a1), upregulates immune genes (CD8a and Hspa1a), and activates mitogen-activated protein kinase (MAPK) signaling. Overall, this work redefines cisplatin therapy by overcoming resistance and enhancing immunity, offering a translational strategy for HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI